Bristol-Myers Squibb Co [NYSE: BMY] traded at a low on 2025-07-21, posting a -1.41 loss after which it closed the day’ session at $46.69.
The results of the trading session contributed to over 9925891 shares changing hands. Over the past one week, the price volatility of Bristol-Myers Squibb Co stands at 2.32% while the volatility over the past one month is 2.05%.
The market cap for BMY stock reached $95.02 billion, with 2.04 billion shares outstanding and 2.03 billion shares in the current float. Compared to the average trading volume of 14.83M shares, BMY reached a trading volume of 9925891 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Bristol-Myers Squibb Co [BMY]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $55.32 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.64. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Bristol-Myers Squibb Co shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 22, 2025. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Neutral. The new note on the price target was released on April 22, 2025, representing the official price target for Bristol-Myers Squibb Co stock. Previously, the target price had yet another raise to $70, while Jefferies analysts kept a Buy rating on BMY stock.
The Price to Book ratio for the last quarter was 5.46, with the Price to Cash per share for the same quarter was set at 5.79. Price to Free Cash Flow for BMY in the course of the last twelve months was 7.26 with Quick ratio for the last quarter at 1.17.
How has BMY stock performed recently?
Bristol-Myers Squibb Co [BMY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.37. With this latest performance, BMY shares dropped by -0.32% in over the last four-week period, additionally sinking by -17.19% over the last 6 months – not to mention a drop of -17.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 45.64, with the RSI for the last a single of trading hit 1.11, and the three-weeks RSI is set at 1.14 for Bristol-Myers Squibb Co [BMY]. The present Moving Average for the last 50 days of trading for this stock 47.45, while it was recorded at 47.14 for the last single week of trading, and 53.89 for the last 200 days.
Bristol-Myers Squibb Co [BMY]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Bristol-Myers Squibb Co [BMY] shares currently have an operating margin of 22.93% and a Gross Margin at 59.16%. Bristol-Myers Squibb Co’s Net Margin is presently recorded at 11.38%.
Bristol-Myers Squibb Co (BMY) Capital Structure & Debt Analysis
According to recent financial data for Bristol-Myers Squibb Co. ( BMY), the Return on Equity (ROE) stands at 31.99%, highlighting impressive shareholder gains. The Return on Assets (ROA) is 5.66%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Bristol-Myers Squibb Co’s Return on Invested Capital (ROIC) is 8.35%, showcasing its effectiveness in deploying capital for earnings.
Bristol-Myers Squibb Co (BMY) Efficiency & Liquidity Metrics
Based on Bristol-Myers Squibb Co’s (BMY) latest financial statements, the Debt-to-Equity Ratio is 2.95%, indicating its reliance on debt financing relative to shareholder equity.
Bristol-Myers Squibb Co (BMY) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Bristol-Myers Squibb Co. (BMY) effectively leverages its workforce, generating an average of $158944.28 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.28% and a Quick Ratio of 1.17%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Bristol-Myers Squibb Co [BMY]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Co go to 72.32%.
Insider trade positions for Bristol-Myers Squibb Co [BMY]
There are presently around $82.11%, or 82.17%% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 186.57 million shares, which is approximately 9.2043%. BLACKROCK INC., holding 158.66 million shares of the stock with an approximate value of $$6.59 billion in BMY stocks shares; and BLACKROCK INC., currently with $$3.8 billion in BMY stock with ownership which is approximately 4.5114%.
